AstraZeneca and GSK have started 2026 on a strong financial footing, delivering first-quarter results that comfortably surpassed market expectations. AstraZeneca reported a core earnings per share (EPS) of $2.58, beating the anticipated $2.53, while GSK posted a core EPS of £0.47, exceeding the projected £0.43. Both pharmaceutical giants have reaffirmed their full-year financial guidance, reflecting […]